The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 28, No. 2, pp. 271-275.
© 1994 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menzin, J
Right arrow Articles by Oster, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menzin, J
Right arrow Articles by Oster, G

Research Articles

Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation

J Menzin, R Richner, D Huse, GA Colditz, and G Oster

OBJECTIVE: To compare the use of healthcare services in patients receiving enoxaparin, a low molecular weight heparin versus those receiving unfractionated heparin as prophylaxis against deep-vein thrombosis (DVT) following total hip replacement surgery. DESIGN: Economic evaluation undertaken in conjunction with a randomized, open-label, parallel group, Phase III clinical trial. SETTING: 32 US acute-care hospitals. PATIENTS: 607 patients undergoing elective total hip replacement. INTERVENTIONS: Enoxaparin 30 mg q12h, enoxaparin 40 mg qd, or unfractionated heparin 5000 units q8h started within 24 hours following surgery and continued for 7 days. MAIN OUTCOME MEASURES: (1) Use of selected tests and treatments for DVT; (2) use of selected tests and treatments related to postoperative bleeding; (3) length of stay in hospital; and (4) readmissions to hospital within 14 days. RESULTS: Although the use of selected tests and treatments related to DVT or postoperative bleeding did not differ significantly between the three treatment groups, mean length of stay in the hospital (following the start of study therapy) was shorter among patients receiving enoxaparin 30 mg (9.5 days; p = 0.01) or 40 mg (9.9 days; p < 0.05) than those receiving unfractionated heparin (11.3 days). There was also a trend toward fewer hospital readmissions in both of the enoxaparin groups. CONCLUSIONS: Compared with unfractionated heparin, use of enoxaparin following total hip replacement may decrease the risk of DVT and length of hospital stay.


This article has been cited by other articles:


Home page
 JBJSHome page
J. R. Lieberman and W. K. Hsu
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2097 - 2112.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
G. K Bell and S. Z Goldhaber
Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement
Vascular Medicine, February 1, 2001; 6(1): 23 - 29.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1994 by Harvey Whitney Books Company.